← Back to Clinical Trials
Recruiting NCT04117100

NCT04117100 Advanced Endo-therapeutic Procedure : Registry-based Observational Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04117100
Status Recruiting
Phase
Sponsor Centre hospitalier de l'Université de Montréal (CHUM)
Condition Zenker Diverticulum
Study Type OBSERVATIONAL
Enrollment 500 participants
Start Date 2018-06-01
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Polypectomy or myotomy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 500 participants in total. It began in 2018-06-01 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Advanced therapeutic endoscopy procedures are of increasing importance to provide minimal invasive treatment for GI diseases. The Centre Hospitalier de l'Université de Montréal as tertiary university center is dedicated to increase the availability of therapeutic endoscopy procedures for our population in Montreal and Quebec. Advanced endotherapeutic endoscopy can replace surgery for treatment of benign and malign GI diseases and the aim of this registry-based study is to improve quality related to advanced endotherapeutic endoscopy, as it will provide quantitative means to assess advanced endotherapeutic practice and may identify practices of low quality (possible intervention) or high quality (desired).

Eligibility Criteria

Inclusion Criteria: * Age \>18 years * Presenting for an elective advanced therapeutic endoscopy (ESD, EMR, advanced polypectomy, POEM or Zenker treatment) * Signed informed consent form Exclusion Criteria: * Patients that are not capable understanding the trial and patients without consent. * Patients with coagulopathy * Patient with poor general health defined as an American Society of Anesthesiologists class greater than three * Pregnancy

Contact & Investigator

Central Contact

Daniel von Renteln, MD, PhD

✉ daniel.von.renteln.med@ssss.gouv.qc.ca

📞 514-890-8000

Principal Investigator

Daniel von Renteln, MD,PhD

PRINCIPAL INVESTIGATOR

Centre Hospitalier Universitaire de Montréal (CHUM)

Frequently Asked Questions

Who can join the NCT04117100 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Zenker Diverticulum. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04117100 currently recruiting?

Yes, NCT04117100 is actively recruiting participants. Contact the research team at daniel.von.renteln.med@ssss.gouv.qc.ca for enrollment information.

Where is the NCT04117100 trial being conducted?

This trial is being conducted at Montreal, Canada.

Who is sponsoring the NCT04117100 clinical trial?

NCT04117100 is sponsored by Centre hospitalier de l'Université de Montréal (CHUM). The principal investigator is Daniel von Renteln, MD,PhD at Centre Hospitalier Universitaire de Montréal (CHUM). The trial plans to enroll 500 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology